Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

DUK 2021 April 19 - 30

Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from SURE UK

Patrick Holmes1; Andrei-Mircea Catarig2; Alice Clark2; Umut Erhan2; Thozhukat Sathyapalan3;
1St George’s Medical Practice, Darlington, UK; 2 Novo Nordisk A/S, Søborg, Denmark; 3 University of Hull, Hull, UK;

The original publication was for the Diabetes UK Professional Conference 2021.